Post-results, we think the disconnect between fundamentals and investor sentiment offers attractive upside for the highest-quality names in our coverage. We’ve become more constructive on the companies below:META (Outperform) - We are adding Meta Platforms to the Best Ideas List and maintain our $9
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will parti...
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...
Tariffs, Tech, NATL: Reciprocal tariffs in Jeopardy?View: The Supereme Court justices appeared skeptical of the Trump administration's arguments that the Executive Branch has the power to levy broad reciprocal tariffs. While we would see a return to a pre-reciprocal tariff regimen as broadly positi
Our target declines to $800 from $900 on lower estimates. With that said, 4Q25 revenue guidance appears low, with both implied impression and pricing growth decelerating against easier comps. In the report, we also discuss the AI = Metaverse narrative that has taken hold, the addition of $30B of new debt and why we are ending share buybacks in our model.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.